“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in GBP
Last close As at 02/06/2023
GBP0.07
▲ 0.30 (4.65%)
Market capitalisation
GBP48m
Shield Therapeutics is a commercial-stage pharmaceutical company. Its proprietary product, Feraccru/Accrufer, is approved by the EMA and FDA for iron deficiency. Shield markets Accrufer in collaboration with Viatris in the United States and in other international markets, it is marketed through Shield’s commercial partners.
The market for iron deficiency is substantial and Feraccru/Accrufer is a unique oral formulation of iron developed to overcome the side-effect profile of salt-based oral iron therapies and provides an alternative treatment to intravenously administered iron.
Managing Director - Head of Content, Healthcare
Greg Madison
CEO
Hans-Peter Rudolf
CFO
Forecast net debt (£m)
4.8
Forecast gearing ratio (%)
182
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (8.2) | (10.6) | (52.4) |
| Relative | (3.8) | (5.6) | (51.6) |
| 52 week high/low | 14.2p/5.6p |
Shield Therapeutics is a UK-headquarted commercial-stage speciality pharmaceutical company focused on the commercialisation of Feraccru/Accrufer (oral ferric maltol), approved by the EMA and FDA to treat iron deficiency in adults, with or without anaemia. Shield launched the product in the United States in July 2021 as part of its self-commercialisation strategy, however, it signed a US co-commercialisation deal for Accrufer with Viatris in December 2022. The commercialisation of Feraccru in Europe, Australia and New Zealand is managed by distribution partner Norgine, and the product has been licensed to ASK Pharm in China, Korea Pharma in South Korea and KYE Pharma in Canada. With the current post-raise (c $36m) capital at hand, Shield is adequately funded to break-even, provided revenue targets are achieved. Q123 was a strong quarter with a 12% q-o-q growth in prescriptions to 10,500. The company guided that the sales team will be at full strength by May 2023 so prescription growth is likely to ramp-up in the coming quarters.
| Y/E Dec | Revenue (£m) | EBITDA (£m) | PBT (£m) | EPS (fd) (p) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2021A | 1.5 | (18.1) | (17.7) | (8.6) | N/A | N/A |
| 2022A | 4.5 | (23.3) | (23.0) | (9.4) | N/A | N/A |
| 2023E | 22.0 | (19.2) | (19.9) | (3.4) | N/A | N/A |
| 2024E | 68.6 | (6.4) | (7.7) | (1.3) | N/A | N/A |
Get access to the very latest content matched to your personal investment style.
